Zoetis | ZTS
Stock Price
157.54
Daily Change
-7.69 -4.65%
Monthly
-5.79%
Yearly
-16.93%
Q1 Forecast
168.42



Peers Price Chg Day Year Date
AbbVie 192.98 -0.58 -0.30% 9.28% Feb/14
Align Technology 207.16 2.26 1.10% -33.13% Feb/14
Bayer 21.35 -0.03 -0.12% -26.12% Feb/17
Bristol-Myers Squibb 53.85 -2.04 -3.65% 8.92% Feb/14
Charles River Laboratories 152.04 -1.15 -0.75% -37.97% Feb/14
Quest Diagnostics 168.90 -0.22 -0.13% 34.34% Feb/14
Henry Schein 76.00 -1.62 -2.09% 0.66% Feb/14
Idexx Laboratories 444.53 -15.23 -3.31% -21.85% Feb/14
Illumina 100.24 -1.54 -1.51% -31.38% Feb/14
IQVIA Holdings 196.05 -0.12 -0.06% -19.48% Feb/14
J&J 156.20 -1.04 -0.66% -1.09% Feb/14
Laboratory Of America 246.72 1.53 0.62% 8.16% Feb/14
Eli Lilly 844.94 -28.28 -3.24% 11.50% Feb/14
Merck 83.02 -1.34 -1.59% -34.39% Feb/14
Neogen 9.83 -0.09 -0.91% -43.89% Feb/14
Pacira 25.44 -1.09 -4.11% -14.23% Feb/14
Patterson Companies 31.03 -0.01 -0.03% 7.22% Feb/14
Pfizer 25.50 -0.15 -0.58% -7.31% Feb/14
Perrigo 24.54 -0.26 -1.04% -22.24% Feb/14
Sanofi 104.03 0.33 0.32% 20.66% Feb/17
Sanofi 54.46 0.46 0.84% 17.39% Feb/14
Dentsply International 18.32 -0.45 -2.37% -43.92% Feb/14
Zoetis 157.54 -7.69 -4.65% -16.93% Feb/14

Indexes Price Day Year Date
US500 6124 -0.44 -0.01% 23.09% Feb/17

Zoetis traded at $157.54 this Friday February 14th, decreasing $7.69 or 4.65 percent since the previous trading session. Looking back, over the last four weeks, Zoetis lost 5.79 percent. Over the last 12 months, its price fell by 16.93 percent. Looking ahead, we forecast Zoetis to be priced at 168.42 by the end of this quarter and at 161.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers.